<ul data-eligibleForWebStory="false"><li>Investors in the healthcare sector should consider the defensive earnings growth amidst uncertain global conditions.</li><li>Pharmaceuticals are facing challenges due to recent tariff announcements by US President Donald Trump, potentially impacting Indian pharmaceutical exports.</li><li>ICICI Pru’s Pharma Healthcare & Diagnostics Fund stands out for delivering strong benchmark-beating returns in the healthcare mutual fund sector.</li><li>The fund is overweight on pharmaceuticals, with significant holdings in Sun Pharma and Divi’s Labs, making it a potential option for investors seeking exposure to the healthcare industry.</li></ul>

ICICI Pru’s Pharma Healthcare & Diagnostics Fund: Tiding over tariffs

Discover more